The Role of Extracellular Vesicles in the Treatment of Prostate Cancer
Source abstract
Abstract
Abstract Prostate cancer (PCa) has become a public health concern in elderly men due to an ever‐increasing number of estimated cases. Unfortunately, the available treatments are unsatisfactory because of a lack of a durable response, especially in advanced disease states. Extracellular vesicles (EVs) are lipid‐bilayer encircled nanoscale vesicles that carry numerous biomolecules (e.g., nucleic acids, proteins, and lipids), mediating the transfer of information. The past decade has witnessed a wide range of EV applications in both diagnostics and therapeutics. First, EV‐based non‐invasive liquid biopsies provide biomarkers in various clinical scenarios to guide treatment; EVs can facilitate the grading and staging of patients for appropriate treatment selection. Second, EVs play a pivotal role in pathophysiological processes via intercellular communication. Targeting key molecules involved in EV‐mediated tumor progression (e.g., proliferation, angiogenesis, metastasis, immune escape, and drug resistance) is a potential approach for curbing PCa. Third, EVs are promising drug carriers. Naïve EVs from various sources and engineered EV‐based drug delivery systems have paved the way for the development of new treatment modalities. This review discusses the recent advancements in the application of EV therapies and highlights EV‐based functional materials as novel interventions for PCa.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Extracellular vesicles in disease · MicroRNA in disease regulation · Nanoplatforms for cancer theranostics
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Urology Renji Hospital Shanghai Jiao Tong University School of Medicine Shanghai 200127 China
Department of Biomedical Engineering Ulsan National Institute of Science and Technology (UNIST) Ulsan 44919 Republic of Korea
Center for Algorithmic and Robotized Synthesis Institute for Basic Science Ulsan Ulsan 44919 Republic of Korea
Funding
National Natural Science Foundation of China
References (100+)
Show source-provided references
1. Siegel R. L. · CA Cancer J Clin · 2023 · 73 · 1710.3322/caac.21763 ↗
2. Bergengren O. · Eur Urol · 2023 · 84 · 19110.1016/j.eururo.2023.04.021 ↗
3. Tkach M. · Cell · 2016 · 164 · 122610.1016/j.cell.2016.01.043 ↗
4. Oey O. · Crit. Rev. Oncol. Hematol. · 2021 · 16710.1016/j.critrevonc.2021.103495 ↗
5. Cocozza F. · Cell · 2020 · 182 · 26210.1016/j.cell.2020.04.054 ↗
6. Ciardiello C. · J Exp Clin Cancer Res · 2019 · 38 · 31710.1186/s13046-019-1317-6 ↗
7. Wang Y. · View · 2023 · 410.1002/VIW.20220048 ↗
8. Feng X. · View · 2023 · 410.1002/VIW.20230004 ↗
9. Guo J. · Cell Rep Med · 2023 · 410.1016/j.xcrm.2022.100881 ↗
10. Gong L. · Adv. Healthcare Mater. · 2023 · 1210.1002/adhm.202202228 ↗
11. Wei H. · Int J Biol Sci · 2021 · 17 · 16310.7150/ijbs.53671 ↗
12. Zhang L. · Biochim. Biophys. Acta, Rev. Cancer · 2019 · 1871 · 45510.1016/j.bbcan.2019.04.004 ↗
13. Zhu Z. · J. Hematol. Oncol. · 2023 · 16 · 3610.1186/s13045-023-01433-5 ↗
14. Yu D. · Mol Cancer · 2022 · 21 · 5610.1186/s12943-022-01509-9 ↗
15. Pang B. · Theranostics · 2020 · 10 · 230910.7150/thno.39486 ↗
16. Camussi G. · J Extracell Vesicles · 2023 · 1210.1002/jev2.12347 ↗
17. Liang H. · Biosens. Bioelectron. · 2023 · 23510.1016/j.bios.2023.115380 ↗
18. Vardaki I. · Clin. Cancer Res. · 2021 · 27 · 325310.1158/1078-0432.CCR-20-4790 ↗
19. Liu P. · J Transl Med · 2023 · 21 · 4010.1186/s12967-022-03860-3 ↗
20. Dai J. · Signal Transduction Targeted Ther. · 2020 · 5 · 14510.1038/s41392-020-00261-0 ↗
21. Akoto T. · Int. J. Mol. Sci. · 2021 · 22 · 352810.3390/ijms22073528 ↗
22. Tan S. · J Exp Clin Cancer Res · 2023 · 42 · 5910.1186/s13046-023-02634-z ↗
23. Iero M. · Cell Death Differ. · 2008 · 15 · 8010.1038/sj.cdd.4402237 ↗
24. Lundholm M. · PLoS One · 2014 · 910.1371/journal.pone.0108925 ↗
25. Kosgodage U. S. · Int. J. Mol. Sci. · 2017 · 18 · 100710.3390/ijms18051007 ↗
26. Corcoran C. · PLoS One · 2012 · 710.1371/journal.pone.0050999 ↗
27. Del Re M. · Eur Urol · 2017 · 71 · 68010.1016/j.eururo.2016.08.012 ↗
28. Vardaki I. · Prostate · 2023 · 83 · 95010.1002/pros.24536 ↗
29. Kato T. · Heliyon · 2020 · 610.1016/j.heliyon.2020.e04138 ↗
30. Bhagirath D. · Clin. Cancer Res. · 2019 · 25 · 653210.1158/1078-0432.CCR-19-0498 ↗
31. Motamedinia P. · PLoS One · 2016 · 1110.1371/journal.pone.0154507 ↗
32. McKiernan J. · JAMA Oncol · 2016 · 2 · 88210.1001/jamaoncol.2016.0097 ↗
33. Yu Q. · J. Biomed. Nanotechnol. · 2018 · 14 · 16810.1166/jbn.2018.2503 ↗
34. Guo T. · Front Cell Dev Biol · 2020 · 810.3389/fcell.2020.602493 ↗
35. Temilola D. O. · Cancers · 2023 · 15 · 396810.3390/cancers15153968 ↗
36. Huang X. · Eur Urol · 2015 · 67 · 3310.1016/j.eururo.2014.07.035 ↗
37. Cao Z. · Biochem. Biophys. Res. Commun. · 2019 · 515 · 34510.1016/j.bbrc.2019.05.120 ↗
38. Warmoes M. · OncoTargets Ther. · 2016 · 710.18632/oncotarget.11535 ↗
39. Kato T. · Urol Oncol. · 2015 · 3310.1016/j.urolonc.2015.04.019 ↗
40. Sequeiros T. · OncoTargets Ther. · 2017 · 8 · 496010.18632/oncotarget.13634 ↗
41. Lapitz A. · J Hepatol · 2023 · 79 · 9310.1016/j.jhep.2023.02.027 ↗
42. Agarwal N. · Lancet · 2023 · 402 · 29110.1016/S0140-6736(23)01055-3 ↗
43. Fizazi K. · N. Engl. J. Med. · 2023 · 388 · 71910.1056/NEJMoa2214676 ↗
44. Beije N. · Eur Urol · 2023 · 84 · 25310.1016/j.eururo.2023.03.038 ↗
45. Lin H. · J Transl Med · 2023 · 21 · 34310.1186/s12967-023-04161-z ↗
46. Choueiri T. K. · Lancet Oncol. · 2023 · 24 · 22810.1016/S1470-2045(23)00049-9 ↗
47. Powles T. · Nat. Med. · 2022 · 28 · 14410.1038/s41591-021-01600-6 ↗
48. Poggio M. · Cell · 2019 · 177 · 41410.1016/j.cell.2019.02.016 ↗
49. Phillips R. · JAMA Oncol · 2020 · 6 · 65010.1001/jamaoncol.2020.0147 ↗
50. Lucien F. · Int J Radiat Oncol Biol Phys · 2022 · 114 · 72510.1016/j.ijrobp.2022.05.037 ↗
51. Kharaziha P. · OncoTargets Ther. · 2015 · 610.18632/oncotarget.3226 ↗
52. Chen C. · J. Hematol. Oncol. · 2018 · 11 · 6410.1186/s13045-018-0605-5 ↗
53. Gomez K. E. · Cancer Res. · 2020 · 80 · 418510.1158/0008-5472.CAN-20-1079 ↗
54. Boman B. M. · Cancer Biol Ther · 2023 · 2410.1080/15384047.2023.2195363 ↗
55. Guo Q. · J. Biol. Chem. · 2022 · 29810.1016/j.jbc.2022.102588 ↗
56. Partin A. W. · JAMA, J. Am. Med. Assoc. · 1997 · 277 · 144510.1001/jama.1997.03540420041027 ↗
57. Yu W. · Ann. Oncol. · 2021 · 32 · 46610.1016/j.annonc.2021.01.074 ↗
58. Fan L. · Oncogene · 2023 · 42 · 55910.1038/s41388-022-02498-1 ↗
59. Ji Y. · Cell. Oncol. · 2023 · 46 · 144510.1007/s13402-023-00822-9 ↗
60. Higano C. S. · EClinicalMedicine · 2023 · 6010.1016/j.eclinm.2023.101993 ↗
61. Lei L. · Heliyon · 2022 · 810.1016/j.heliyon.2022.e12114 ↗
62. Soekmadji C. · Proteomics · 2017 · 1710.1002/pmic.201600427 ↗
63. Shan G. · Exp. Mol. Med. · 2020 · 52 · 180910.1038/s12276-020-0431-z ↗
64. Dearnaley D. P. · Lancet Oncol. · 2014 · 15 · 46410.1016/S1470-2045(14)70040-3 ↗
65. Hackman G. · Eur Urol · 2019 · 76 · 58610.1016/j.eururo.2019.07.001 ↗
66. Boevé L. M. S. · Eur Urol · 2019 · 75 · 41010.1016/j.eururo.2018.09.008 ↗
67. Parker C. C. · Lancet · 2018 · 392 · 235310.1016/S0140-6736(18)32486-3 ↗
68. Ost P. · J. Clin. Oncol. · 2018 · 36 · 44610.1200/JCO.2017.75.4853 ↗
69. Wang X. · J Extracell Vesicles · 2023 · 1210.1002/jev2.12342 ↗
70. Chen G. · Nature · 2018 · 560 · 38210.1038/s41586-018-0392-8 ↗
71. Won S. · J Extracell Vesicles · 2023 · 1210.1002/jev2.12357 ↗
72. Dong L. · Biochim. Biophys. Acta, Rev. Cancer · 2019 · 1871 · 34210.1016/j.bbcan.2019.01.008 ↗
73. Dong L. · J Extracell Vesicles · 2020 · 1010.1002/jev2.12044 ↗
74. Urabe F. · Int J Urol · 2018 · 25 · 53310.1111/iju.13594 ↗
75. Kosaka N. · J. Clin. Invest. · 2016 · 126 · 116310.1172/JCI81130 ↗
76. Ding L. · Clin. Transl. Med. · 2023 · 13 · 115610.1002/ctm2.1156 ↗
77. Huang S. · Apoptosis · 2023 · 28 · 137210.1007/s10495-023-01872-y ↗
78. Naranjo N. M. · Biochem. J. · 2021 · 478 · 390510.1042/BCJ20210580 ↗
79. Li Q. · Cell Cycle · 2021 · 20 · 253110.1080/15384101.2021.1992853 ↗
80. Zheng Y. · Cell Biol. Int. · 2020 · 44 · 103710.1002/cbin.11303 ↗
81. Li T. · J. Cell. Biochem. · 2020 · 121 · 211810.1002/jcb.28239 ↗
82. Read J. · Eur J Cancer · 2017 · 70 · 6210.1016/j.ejca.2016.10.017 ↗
83. Khanna K. · Prostate Cancer Prostatic Dis · 2021 · 24 · 80210.1038/s41391-021-00319-2 ↗
84. Ishizuya Y. · Biochem. Biophys. Res. Commun. · 2020 · 523 · 58810.1016/j.bbrc.2019.12.084 ↗
85. Cao Y. · Nat. Rev. Drug Discovery · 2023 · 22 · 47610.1038/s41573-023-00671-z ↗
86. Kelly W. K. · J. Clin. Oncol. · 2012 · 30 · 153410.1200/JCO.2011.39.4767 ↗
87. Tannock I. F. · Lancet Oncol. · 2013 · 14 · 76010.1016/S1470-2045(13)70184-0 ↗
88. Pan Y. · Small · 2023 · 1910.1002/smll.202205739 ↗
89. Wu M. · Mol Cancer · 2019 · 18 · 5310.1186/s12943-019-0964-8 ↗
90. Krishn S. R. · J Extracell Vesicles · 2020 · 910.1080/20013078.2020.1763594 ↗
91. Luo J. Q. · Cell Death Dis. · 2023 · 14 · 50210.1038/s41419-023-06007-4 ↗
92. Hu C. · PET Clin · 2022 · 17 · 55510.1016/j.cpet.2022.07.001 ↗
93. Dong L. · J Nucl Med · 2021 · 63 · 24810.2967/jnumed.121.262411 ↗
94. Dong L. · Med Oncol · 2020 · 37 · 8910.1007/s12032-020-01412-7 ↗
95. Zhang J. · Comput Struct Biotechnol J · 2023 · 21 · 66510.1016/j.csbj.2022.12.049 ↗
96. Machado C. M. L. · J. Controlled Release · 2023 · 364 · 31210.1016/j.jconrel.2023.10.038 ↗
97. Dong L. · Curr Opin Oncol · 2021 · 33 · 23110.1097/CCO.0000000000000719 ↗
98. Wieckowski E. U. · J. Immunol. · 2009 · 183 · 372010.4049/jimmunol.0900970 ↗
99. Abusamra A. J. · Blood Cells Mol Dis · 2005 · 35 · 16910.1016/j.bcmd.2005.07.001 ↗
100. Miyazaki T. · Oncogenesis · 2018 · 7 · 710.1038/s41389-017-0022-6 ↗